Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma

Acta Oto-Laryngologica

Volumn 130, Issue 7, 2010, Pages 756-762

  Zhang, Baitao ^a   Li, Xiaoming ^a,b   Lu, Xiuying ^b  

^a JILIN UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

Author keywords

Disease free survival; FDG; Local control; Meta analysis; Overall survival; PET; Primary tumor; Prognostic factors

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAXILLA CANCER; MEDICAL LITERATURE; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; RADIOLOGICAL PARAMETERS; REVIEW; SQUAMOUS CELL CARCINOMA; STANDARDIZED UPTAKE VALUE; SYSTEMATIC REVIEW;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 77953929290     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016480903402981     Document Type: Review

References (20)

1. Lydiatt WM, Shah JP, Hoffman HT. AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the Head and Neck Sites Task Force. Head Neck 2001;23:607-612
2. Osman I, Sherman E, Singh B, Venkatraman E, Zelefsky M, Bosl G, et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002;20:2980-2987
3. Izzo JG, Papadimitrakopoulou VA, Liu DD, den Hollander PL, Babenko IM, Keck J, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198-205.
4. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356
5. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332
6. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995;36:252-258
7. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-1555
8. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucosepositron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-3206
9. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat L, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the LASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
10. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907-1911
11. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-135
12. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004;59:1295-1300
13. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130:1361-1367
14. Kim SY, Roh JL, Kim MR, Kim JS, Choi SH, Nam SY, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 2007;48:752-757
15. Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB, et al. 2-[(18)F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 2007;33: 790-795
16. Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, et al. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 2009;31:195-201.
17. Torizuka T, Tanizaki Y, Kanno T, Futatsubashi M, Naitou K, Ueda Y, et al. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer. AJR Am J Roentgenol 2009;1924:156-160.
18. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, EI-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20:1398-1404
19. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002;86:512-516
20. Burk D, Woods M, Hunter J. On the significance of glucolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst 1967;38:839-863